After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2700 |
| Open | 2.2600 |
| Bid | 2.2200 x 900 |
| Ask | 2.4900 x 1100 |
| Day's Range | 2.2301 - 2.3400 |
| 52 Week Range | 0.5800 - 2.4600 |
| Volume | |
| Avg. Volume | 270,150 |
| Market Cap | 137.643M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5000 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ARAV
Related Research
- Aravive, Inc.Weekly Stock ListArgus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.RatingFair ValueEconomic Moat6 days agoArgus Research
- Simply Wall St.
Aravive (NASDAQ:ARAV) shareholders are up 14% this past week, but still in the red over the last five years
While not a mind-blowing move, it is good to see that the Aravive, Inc. ( NASDAQ:ARAV ) share price has gained 20% in...
- Zacks
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash PositionHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates. "As we reflect on a productive 2022, Aravive remains committed to driving progres
